Indolent Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Indolent Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-02-26FDA Approved: BENDAMUSTINE HYDROCHLORIDE — Supplemental Application (Baxter Healthcare Corporation)
FDA approved a supplemental application for bendamustine hydrochloride (Baxter Healthcare Corporation) under NDA 216078.